BRAF and melanoma: Therefore, Wang et al. established BRAF-mutant melanoma PDX models resistant to BRAF and MEK inhibitors and reduced their growth with mTOR inhibitors.194 Aberrant activation of STAT3 inhibitor has been a target for NSCLC because it contributes to the secondary resistance against EGFR-TKI.